Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant support for drug innovation, particularly in pediatric and rare disease medications, providing market exclusivity periods to encourage research and development [2][7]. Group 1: Drug Innovation and Market Exclusivity - The new regulations grant a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, contingent on the commitment to ensure drug supply [2][3]. - The regulations signal strong governmental support for drug innovation, particularly in under-researched areas, which is expected to enhance the overall innovation ecosystem in the pharmaceutical industry [2][3]. - The company emphasizes innovation as a core driver of its development, establishing a research model based on clinical practice and traditional Chinese medicine theories [2][3]. Group 2: Company’s R&D Capabilities - The company possesses capabilities in developing compound, component, and single-entity traditional Chinese medicine, with 17 patented products covering major clinical disease systems [3][4]. - The company plans to increase investment in pediatric and rare disease drug development following the implementation of the new regulations, with several products already in the pipeline [3][4]. - Currently, the company has submitted new drug applications for several innovative traditional Chinese medicines and has multiple products in clinical research phases [3][4]. Group 3: Quality Control and Compliance - The new regulations impose stricter requirements on the production and sale of traditional Chinese medicine, necessitating improved quality control systems from source to end [4][5]. - The company is actively responding to national policies on standardizing and industrializing traditional Chinese medicine, focusing on quality control from the research and design stages [4][5]. - The company has established a comprehensive quality management system based on Good Manufacturing Practice (GMP), ensuring all products meet quality standards [5][6]. Group 4: Future Directions - The company aims to enhance innovation investment, focusing on major diseases, pediatric, and rare disease medications to meet unmet clinical needs [7]. - The company plans to optimize its quality control system in response to the new regulations, ensuring the safety and efficacy of every product [7]. - The company is committed to promoting internationalization of traditional Chinese medicine, aiming to benefit global patients with innovative products [7].